RESEARCH-USE BIOSIMILAR ANTIBODY
Epratuzumab
Monoclonal antibody · IgG1
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.
TARGETSIGLEC2
YMonoclonal antibody
CATALOGSC-BS-566
CATALOG NUMBERSC-BS-566
MOLECULAR WEIGHTApprox. 146.58 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases.
Epratuzumab is a recombinant research-use antibody directed against SIGLEC2.